Ovid Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The company is advancing a diversified pipeline of small molecule therapies for neurological and neuropsychiatric disorders, with OV329 and OV4071 as lead assets. Key clinical milestones are expected in the next 6–24 months, supported by strong financial runway and a strategic approach to partnerships.
-
The meeting covered director election, executive compensation, and auditor ratification, with all proposals approved. No shareholder questions were raised, and quorum was established with 75.7% of shares represented.
-
KCC2 direct activation is a transformative approach for psychotic disorders, with OV4071 showing strong preclinical efficacy and safety. The clinical strategy uses translational biomarkers for rapid proof-of-concept in schizophrenia, Parkinson’s disease psychosis, and Lewy body dementia, backed by broad IP and significant commercial potential.
-
The company is advancing OV329, a novel GABA-AT inhibitor, into Phase II for epilepsy with promising safety and efficacy data, while also progressing OV4071, a KCC2 activator, into Phase I for CNS disorders including psychosis. Interim and pivotal data readouts are expected over the next year.
-
The company is advancing a CNS-focused pipeline with differentiated mechanisms, highlighted by OV329 for epilepsy, which shows strong efficacy and tolerability, and OV4071, a KCC2 activator targeting psychosis. Key clinical milestones are expected over the next 6–18 months.
Fiscal Year 2025
-
Regulatory clearance for OV4071 and strong safety data for OV329 drive pipeline expansion into rare epilepsies, supported by $60M PIPE financing and a projected cash runway into 2029. New clinical trials and broad market opportunities are anticipated.
-
Phase I results for OV329 in healthy volunteers showed a strong safety profile, no ocular toxicity, and robust GABAergic inhibition exceeding that of vigabatrin. The data support advancing to a phase II-A trial in treatment-resistant focal onset epilepsy, with a 7 mg dose selected for optimal efficacy and safety.
-
OV329, a next-generation GABA-AT inhibitor, is advancing through a biomarker-rich phase I study with a readout expected in late Q3 2025. Early data show strong safety and target engagement, supporting plans for phase II-A in drug-resistant focal seizures and a differentiated market position.
-
The presentation detailed a differentiated CNS pipeline focused on precision small molecules, highlighting OV329’s progress toward phase II for treatment-resistant epilepsy and the first-in-class KCC2 activators targeting psychosis in Parkinson’s and Lewy body dementia. Key milestones include multiple clinical readouts in 2024–2025 and a strong cash position to support ongoing development.
-
The presentation detailed a differentiated neurotherapeutics pipeline, highlighting OV329’s promising safety and efficacy profile in epilepsy and the KCC2 platform’s first-in-human milestone for psychosis. Multiple clinical readouts and strong capital position support strategic growth.
-
The conference highlighted a robust pipeline targeting neuronal hyperexcitability, with OV-329 advancing toward key safety and biomarker data in 2024 and a diverse KCC2 platform entering first-in-human trials. The paused ROCK2 program may resume pending external trial outcomes.
Fiscal Year 2024
-
A robust pipeline of direct KCC2 activators is advancing toward first-in-human studies, targeting neuronal hyper-excitability in CNS disorders. OV350 leads with a phase I trial planned for early 2025, supported by strong preclinical efficacy and safety data. Strategic focus includes broad indication potential, disciplined resource use, and partnering flexibility.